Feasibility of Isolating P16 Expression

Completed

Conditions studied: Childhood Cancer

In brief

Expression of the cell cycle regulator p16INK4a increases with age and toxic stressors. In mice, both radiation and chemotherapy are known to increase p16. Due to its influence on age-related regenerative capacity, p16 is an excellent candidate biomarker of physiologic reserve that may identify patients able to withstand the stressor of chemotherapy (low p16) from those unlikely to tolerate chemotherapy (high p16). That is, expression of p16 may predict physiologic, rather than chronologic, age. Such findings could have implications for care of cancer survivors and treatment decision-making in cancer patients. STUDY OBJECTIVE: This is an observational pilot study to determine the feasibility of isolating p16INK4a in CD3+ T lymphocytes in adults treated with chemotherapy for cancer during childhood.

Key facts

Study ID

NCT03160768

Run by

St. Jude Children's Research Hospital

People needed

85

Starts

2017-05-25

Expected to finish

2019-05-02

Last updated by the study team

2019-05-06

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Enrolled in the SJLIFE study at St. Jude children's Research Hospital.
• Survivor of childhood cancer.
• Is 18 years of age and older.
• No evidence of cancer recurrence.
• Received prior chemotherapy (prior radiotherapy is allowed).

You may not qualify if…

• Inability or refusal to give consent.

Where it is running

• St. Jude Children's Research Hospital — Memphis, Tennessee, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.